RopesTalk

On this episode of Ropes & Gray’s California Law for Asset Managers podcast series, asset management partner Catherine Skulan and employment partners Greg Demers, Richard Kidd and associate Patrick Maher, discuss recent developments in California employment law that may impact asset managers and their portfolio companies. The group will address a new California noncompete statute, including a recent case that gives some insight into the contours of the law, and new California requirements to implement comprehensive workplace violence prevention plans. 

On this fourth episode of Ropes & Gray’s Health Care Transaction Laws Unwrapped podcast series, health care attorneys Ranee Adipat, Jenn Romig and Jaclyn Freshman discuss the latest updates to state health care transaction laws on the West Coast. The team explores recent developments in California and Oregon, including California's AB 3129 (recently vetoed by Governor Newsom) and Oregon's proactive enforcement. The episode offers practical advice on navigating these complex regulatory environments, the impact on deal timelines, and strategic considerations for health care entities and private equity investors. 

On this episode of Ropes & Gray’s podcast series, Non-binding Guidance, life sciences regulatory and compliance partner Greg Levine and counsel Beth Weinman are joined by appellate and Supreme Court practice head Doug Hallward-Driemeier to explore the Supreme Court's recent landmark decision in Loper Bright, which ended the long-standing practice of Chevron deference. Learn how this ruling has reshaped the regulatory landscape for federal agencies like the FDA and what it means for companies navigating these changes, including implications for Administrative Procedure Act (APA) challenges going forward. 

Dr. Brennan Jacoby, a philosopher and founder of Philosophy at Work, chats about weaving ethics into organizational culture from his global travels. He highlights the philosophy of trust and how compliance teams can nurture it. Listeners learn about his Ethics Lab workshops that empower meaningful ethical discussions. The conversation dives into the significance of critical thinking, empathy, and communication in navigating ethical dilemmas. Jacoby provides practical exercises for teams to enhance their engagement and foster a culture of trust.

On this episode of the R&G Tech Studio podcast, host Brad Flint, co-leader of Ropes & Gray’s venture capital and emerging companies practice, is joined by Raj Banerjee, a partner in both the venture capital and emerging companies practice, as well as the IP transactions group at Ropes & Gray. Raj shares insights from his extensive experience as a life sciences lawyer, focusing on the intersection of AI and life sciences. He discusses the significant trends in AI investment, the impact of AI on corporate America, and how these developments are reshaping the venture investing world. Raj also highlights the role Ropes & Gray plays in helping clients navigate these exciting changes, from structuring licensing deals to providing specialized regulatory advice. 

On this third episode of Ropes & Gray’s Health Care Transaction Laws Unwrapped podcast series, health care attorneys Brett Friedman, Ben Wilson and Sharon Jaquez discuss the latest updates to state health care transaction laws on the East Coast. The team explores recent developments in New York, Massachusetts, Connecticut and Pennsylvania, examining the implications of new and pending legislation on health care transactions. They provide practical insights on navigating the evolving regulatory landscape, the impact on deal timelines, confidentiality, and strategic considerations for health care entities and private equity investors. 

On this episode of Ropes & Gray's ITC-focused podcast series, Talkin' Trade, IP litigators Matt Rizzolo, Matt Shapiro, and Cole Dunn delve into the landmark Supreme Court decision in Loper Bright and its potential impact on Section 337 proceedings. They provide a comprehensive overview of Chevron deference, its historical application, and explore how its recent dismissal may reshape ITC practices. From defining "articles that infringe" to the nuances of "domestic industry," they break down the potential changes and challenges ahead. 

Join Adam Churltaub, Chief Engagement and Strategy Officer at the Society of Corporate Compliance and Ethics, and Krista Wolf, an employee engagement expert at Agilent Technologies. They delve into how corporate culture serves as the DNA of organizations, shaping compliance behaviors and attitudes. The discussion highlights the significance of fostering a positive culture to enhance compliance effectiveness and the role of data in understanding cultural dynamics. Innovative strategies for engaging diverse teams and promoting a speak-up culture are also explored.

On this episode of Ropes & Gray’s Health Care Transaction Laws Unwrapped podcast series, health care attorneys Debbie Gersh, Jenn Romig and Shanzeh Daudi discuss recent developments and trends related to state health care transaction laws in the Midwest. With recent enactments in Illinois, Indiana and Minnesota, and pending legislation in Pennsylvania, Debbie, Jenn and Shanzeh provide crucial insights into the new regulatory frameworks affecting mergers, acquisitions and affiliations in the region. Learn about the implications of these laws for health care entities/facilities, provider organizations and private equity investors, including materiality thresholds, notification processes and potential regulatory hurdles. 

On this episode of Women @ RopesTalk hosted by health care and data partner Christine Moundas, IP transactions and licensing partner Megan Baca engages in a fascinating conversation with Laura Berner, COO of TRex Bio. Laura shares her unique journey from practicing law at Ropes & Gray to embracing roles in business development and operations within the biotech sector. She discusses her experiences at Genentech, Roche, and Myovant Sciences, shedding light on the transition from legal to business roles and the challenges of working in both large pharmaceutical companies and smaller biotech startups. Laura also offers her perspective on the importance of continuous learning and growth, her approach to decision-making, and her vision as a leader in a preclinical-stage company.